This article has Open Peer Review reports available.
Blastomatoid pulmonary carcinosarcoma: report of a case with a review of the literature
© Schaefer et al.; licensee BioMed Central Ltd. 2012
Received: 25 June 2012
Accepted: 22 September 2012
Published: 25 September 2012
Pulmonary carcinosarcoma is a biphasic tumour with an unfavourable prognosis. The differential diagnosis includes pulmonary blastoma and is often challenging.
We here describe a case of blastomatoid pulmonary carcinosarcoma in a 58-year-old patient, who underwent surgical resection. Histopathological examination revealed immature glandular epithelium resembling high-grade fetal adenocarcinoma expressing epithelial markers and membranous beta-catenin, and blastomatoid spindle cells with partial rhabdomyosarcoma-like differentiation. Both elements expressed p53, MDM2, and cyclin-dependent kinase 4 (CDK4), but not thyroid-transcription factor 1 (TTF-1). Mutation analysis of KRAS, EGFR, and beta-catenin revealed no mutations. Comparative genomic hybridization detected +1q, +6p, +6q24qter, +8q, +11q12q14, +11q23qter, +12q12q21, +12q24qter, +17q, +20q, -5q14q23, -9p13pter, -13q21q21, and amplifications at 12q14q21, 15q24qter, 20q11q12.
The observed molecular and cytogenetic findings may provide additional tools for the differential diagnosis of biphasic pulmonary neoplasms. Furthermore, TP53, MDM2, CDK4, and PTPN1 may be involved in tumourigenesis.
KeywordsLung biphasic, Carcinosarcoma, Pulmonary blastoma, Comparative genomic hybridization
The differential diagnosis of biphasic pulmonary tumours consisting of a mesenchymal component combined with adenocarcinoma includes pulmonary blastoma and carcinosarcoma [1–3]. The degree and type of differentiation of both elements, immunohistochemical staining and molecular genetic findings are of help in establishing the correct diagnosis, which may be challenging in some cases. However, the developmental origin and the correct classification of pulmonary blastoma and carcinosarcoma is still being discussed on . Here, we describe a case of pulmonary carcinosarcoma of the blastomatoid variant in a 58-year-old patient who underwent pneumonectomy. We present the clinico-pathological characteristics and the results of immunohistochemistry, mutation analysis, chromogenic in situ hybridization (CISH), and comparative genomic hybridization (CGH) of this rare entity with a review of the literature, providing helpful diagnostic tools in the differential diagnosis.
Immunohistochemically, the glandular structures expressed epithelial markers including epithelial membrane antigen (EMA; Dako, Glostrup, Denmark), pan-cytokeratin (Dako), carcinoembryonic antigen (CEA; Zytomed Systems, Berlin, Germany), CK7 (Dako), and focal p63 (BioGenex, San Ramon, CA). Thyroid transcription factor 1 (TTF-1; Dako) was not expressed. Staining for beta-catenin (Medac, Wedel, Germany) demonstrated a membranous expression in the epithelial structures. The spindle cell component expressed vimentin (Dako), desmin (Invitrogen, Camarillo, CA) in 10% of tumour cells, and myogenin (Dako) in 10% of tumour cells indicating partial rhabdomyosarcoma-like differentiation, EGFR (Invitrogen), and CD56 (Invitrogen). Both components expressed p53 (Dako), MDM2 (Zytomed Systems), and cyclin-dependent kinase 4 (CDK4; Zytomed Systems). Proliferative activity was assessed by Ki67 (Zytomed Systems) immunostaining and was estimated at 60%.
The diagnosis of the blastomatoid variant of pulmonary carcinosarcoma was established and the tumour was finally staged at pT3, pN0 (0/15), pMX, G3, R0, UICC stage 2b. The patient recovered well and was discharged 21 days after surgery. An optional adjuvant therapy was discussed with the patient, but he refused. Currently the patient is doing well and there is no evidence of tumour relapse 30 months after the resection.
The differential diagnoses of biphasic pleuropulmonary tumours in adults include glandular malignant peripheral nerve sheath tumour (MPNST), synovial sarcoma, and malignant mesothelioma [2, 3, 5]. When only small biopsy specimen are available and both components are not represented, carcinosarcoma may also be misinterpreted as an either entirely epithelial or mesenchymal neoplasm . In glandular MPNST, rhabdomyosarcomatous elements may be present, but the tumour usually displays intestinal type-epithelium with goblet cells. Furthermore, the sarcomatoid part of MPNST expresses S100 protein and vimentin, and the tumour is associated with neurofibromatosis type 1 . Synovial sarcoma was ruled out because the characteristic SYT-SSX fusion gene was not detected . Malignant mesothelioma was also ruled out by negative staining for mesothelial markers (i. e. calretinin, D2-40).
The clinicopathologic and molecular genetic characteristics of pulmonary blastoma, pulmonary carcinosarcoma, and the present case
M:F = 2:1
0.25-0.5% of pulmonary neoplasms
Upper lobe, central/endo-bronchial or peripheral
Poor (5-year survival rate 16%)
Low-grade adenocarcinoma of fetal lung type/well-differentiated fetal adenocarcinoma
Undifferentiated blastema, striated or smooth muscle, cartilage, bone, yolk sac-like areas, melanocytic differentiation, morules
EMA, pan-CK, CEA, TTF-1, CK7, nuclear/cytoplasmatic beta-catenin
Vimentin, desmin, SMA, myoglobin, S-100; morules: synaptophysin, chromogranin A, CD10
Trisomies 2 and 8, allelic imbalances at 14q24q32 and 17p11p13
TP53, MDM2, beta-catenin (no EGFR or KRAS)
M:F = 7:1
0.2-0.4% of pulmonary neoplasms
Upper lobe, central/endo-bronchial or peripheral
Poor (5-year survival rate 20-50%)
Squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma,large cell carcinoma
Spindle cells, fibrosarcoma, rhabdomyosarcoma, chondrosarcoma, osteosarcoma, blastema-like stroma
EMA, pan-CK, CK7, CAM5.2, CK5/6, p63, napsin, synaptophysin, chromogranin, CD56, membranous beta-catenin (TTF-1 negative)
Desmin, myogenin, myoD1, S-100
Gains: 1q, 3q, 5p, 8q, 12p; Losses: 3q, 5q, 17p
TP53 (no KRAS or beta-catenin)
Present case: blastomatoid variant of carcinosarcoma
Right upper lobe
Alive, no relapse (22 months)
High-grade adenocarcinoma of fetal lung type
Spindle cells, rhabdomyosarcoma
EMA, pan-CK, CK7, CEA, MDM2, CDK4, focal p63, membranous beta-catenin (TTF-1 negative)
Vimentin, desmin, EGFR, CD56, myogenin, MDM2, CDK4
Gains: 1q, 6p, 6q24qter, 8q, 11q12q14, 11q23qter, 12q12q21, 12q24qter, 17q, 20q; Losses: 5q14q23, 9p13pter, 13q21q21; Amplifications: 12q14q21, 15q24qter, 20q11q12
TP53, MDM2, CDK4 (no EGFR, KRAS or beta-catenin)
In the case presented here, the gross appearance and localization of the tumour were not helpful in the differential diagnosis, since both pulmonary blastoma and carcinosarcoma are known to arise either central/peribronchial or in the periphery of the lung, forming a large bulk [2, 8]. Pulmonary carcinosarcoma is reported to arise in elderly men between 50–80 years who are heavy smokers, as our patient [1, 2, 8, 9], whereas the mean age of patients with pulmonary blastoma is around 35–50 years [2, 10, 11]. On microscopic examination, undifferentiated adenocarcinoma, intermixed rhabdomyosarcoma-like spindle cells, and extensive necroses may be observed in both entities [2, 8]. It has been proposed to classify pulmonary blastoma into three groups: biphasic pulmonary blastoma, well-differentiated fetal adenocarcinoma, and pleuropulmonary blastoma, the latter arising only in children . Biphasic pulmonary blastoma enters the differential diagnosis of carcinosarcoma as it combines malignant epithelial and mesenchymal components .
The epithelial component in the present case showed focal cellular atypia, mitotic figures, and branching glands composed of columnar cells with palisading elliptic nuclei with subnuclear vacuoles resembling high-grade fetal adenocarcinoma as described for carcinosarcoma . In contrast, well-differentiated or low-grade adenocarcinoma would be a typical feature of pulmonary blastoma . Morules, as described to occur in 43% of biphasic pulmonary blastomas, were not present [2, 11]. The mesenchymal component displayed a rather immature, blastoma-like differentiation. Expression of TTF-1 occuring rather in the well differentiated fetal adenocarcinoma of pulmonary blastoma, was not observed in the present case, favouring the diagnosis of carcinosarcoma . Furthermore, it has been demonstrated that low-grade adenocarcinoma of the fetal lung type/well-differentiated fetal adenocarcinoma constantly shows aberrant nuclear or cytoplasmic localization of beta-catenin, whereas high-grade adenocarcinoma of the fetal lung type/clear cell adenocarcinoma with fetal lung features shows the same membranous localization of beta-catenin as conventional pulmonary adenocarcinomas, which could also be observed in the present case .
Previous immunohistochemical and molecular analyses in pulmonary carcinosarcoma revealed mutations of TP53, but not of KRAS or beta-catenin[1, 2]. To our knowledge, mutations of EGFR, MDM2 or CDK4 have not yet been investigated in this entity. Cytogenetic aberrations reported for this entity include allelic gains at 1q, 3q, 5p, 8q, 12p, and losses at 3q, 5q, 17p . Pulmonary blastoma on the other hand is characterized by TP53, MDM2, and beta-catenin mutations, whereas EGFR and KRAS mutations are usually not detected [1, 10, 12, 13]. Furthermore, trisomies 2 and 8, and allelic imbalances at 14q24q32 and 17p11p13 are reported for this tumour entity [2, 10, 12].
Immunohistochemically, an expression of p53 was detected in the present case consistent with an underlying TP53 mutation, but no EGFR, KRAS or beta-catenin mutation were found. Additionally, we observed a high number of chromosomal aberrations by CGH including gains at 1q, 6p, 6q24qter, 8q, 11q12q14, 11q23qter, 12q12q21, 12q24qter, 17q, 20q, losses at 5q14q23, 9p13pter, 13q21q21, and amplifications at 12q14q21, 15q24qter, 20q11q12. Interestingly, the observed gains at 1q, 8q, and losses at 5q are among the aberrations described for pulmonary carcinosarcoma . The present case, however, displayed several more imbalances that have not yet been described for pulmonary carcinosarcoma. The high number of chromosomal imbalances indicates a high degree of chromosomal instability and tumour progression in the blastomatoid variant of carcinosarcoma. Furthermore, the observed imbalances may be of help in the differential diagnosis, in particular if +1q, +8q, and -5q are detected. The developmental origin of both tumour components is unclear and an origin from two or more stem cells (multiclonal hypothesis) or an origin from a single totipotential stem cell that differentiates into separate epithelial and mesenchymal directions (monoclonal hypothesis) seems possible . Previous analyses in pulmonary carcinosarcoma , biphasic pulmonary blastoma , and carcinosarcomas of other localizations  provide evidence that the epithelial and mesenchymal component of these biphasic tumours harbour a different morphology, but are monoclonal in origin.
The observed chromosomal changes may give insight into tumourigenesis and help to identify possible candidate genes. The amplicon 12q13q21 (including the observed 12q14q21) is also typically detected in different types of sarcoma, particularly in liposarcoma and osteosarcoma . It harbors several genes, of which the amplifications or mutations of MDM2 and CDK4 were confirmed immunohistochemically and by CISH analysis in the present case and may play a role in tumourigenesis [10, 16]. Over-expression of MDM2 has previously been observed in 83% of biphasic pulmonary blastomas, but it has so far not been studied in pulmonary carcinosarcomas . Furthermore, the observed amplicon at 15q24qter has also been reported in small-cell lung cancers, while the amplicon detected here at 20q11q12 includes the PTPN1 gene located at 20q12 which serves as a non-receptor tyrosine phosphatase involved in growth regulation . It has been found to be over-expressed in 72% of breast carcinomas .
As reported, complete surgical resection is the treatment of choice in patients with resectable tumours . Chemotherapy and radiation can be used in an adjuvant setting although specific regimens do not exist [2, 3]. In the present case, the mesenchymal component slightly predominated and an adjuvant therapy according to guidelines for soft tissue sarcomas was discussed. However, since complete resection was achieved, lymph node or distant metastases were ruled out, and the patient refused, no adjuvant therapy was applied.
The present case illustrates the diagnostic difficulties in differentiating pulmonary carcinosarcoma from biphasic pulmonary blastoma, in particular if the carcinosarcoma contains fetal adenocarcinoma and a blastomatoid mesenchymal component. It also highlights the usefulness of additional molecular and genomic analyses. From our findings we conclude that similar to pulmonary blastoma pulmonary carcinosarcoma may harbour MDM2 and lack EGFR mutations. Therefore, presence of TP53, MDM2, and lack of KRAS and EGFR mutations may not be helpful in the differential diagnosis of both entities. Only the presence or absence of beta-catenin mutations will serve as a useful diagnostic tool in certain cases. In the present case, the diagnosis was discussed with reference pathologists who favoured the diagnoses of either pulmonary blastoma or blastomatoid carcinosarcoma. Although high-grade fetal adenocarcinoma was not present in every tumour sample, the diagnosis of pulmonary carcinosarcoma was finally made based on the mutation analyses, particularly of beta-catenin.
In conclusion, the presence of high-grade fetal adenocarcinoma without TTF-1 expression, lack of beta-catenin mutation, and detection of 1q, +8q, and -5q by CGH in a biphasic lung tumour in adult patients favours the diagnosis of pulmonary carcinosarcoma. Furthermore, mutations of TP53, MDM2, CDK4, and PTPN1 may play a role in development and progression of this tumour entity.
Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Series Editor of this journal.
The authors thank Prof. Dr. A. Tannapfel, MD, Department of Pathology, Ruhr University Bochum, Germany, Prof. Dr. I. Leuschner, MD, Department of Pathology, University of Kiel, Germany, and Dr. M. Bettstetter, MD, Molecular Pathology Southern Bavaria, Germany, for their contribution to the diagnosis.
- Nakatani Y, Miyagi Y, Takemura T, Oka T, Yokoi T, Takagi M, Yokoyama S, Kashima K, Hara K, Yamada T, et al: Aberrant nuclear/cytoplasmic localization and gene mutation of beta-catenin in classic pulmonary blastoma: beta-catenin immunostaining is useful for distinguishing between classic pulmonary blastoma and a blastomatoid variant of carcinosarcoma. Am J Surg Pathol. 2004, 28: 921-927. 10.1097/00000478-200407000-00012.View ArticlePubMedGoogle Scholar
- Weissferdt A, Moran CA: Malignant biphasic tumors of the lungs. Adv Anat Pathol. 2011, 18: 179-189. 10.1097/PAP.0b013e318216980c.View ArticlePubMedGoogle Scholar
- Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC: Pathology and genetics of tumours of the lung, pleura, thymus and heart. 2004, Lyon: IARC PressGoogle Scholar
- Schaefer IM, Enders C, Polten A, Haller F, Frolich AM, Cameron S, Schuler P, Schweiger P, Gunawan B, Beham A, et al: Common Genomic Aberrations in Basaloid Squamous Cell Carcinoma and Carcinosarcoma of the Esophagus Detected by CGH and Array CGH. Am J Clin Pathol. 2011, 135: 579-586. 10.1309/AJCPZ1O7UUUISPNR.View ArticlePubMedGoogle Scholar
- Weiss SW, Goldblum JR: Enzinger and Weiss's soft tissue tumors. 2008, St. Louis: Mosby ElsevierGoogle Scholar
- Nagasaka T, Lai R, Sone M, Nakashima T, Nakashima N: Glandular malignant peripheral nerve sheath tumor: an unusual case showing histologically malignant glands. Arch Pathol Lab Med. 2000, 124: 1364-1368.PubMedGoogle Scholar
- Mirzoyan M, Muslimani A, Setrakian S, Swedeh M, Daw HA: Primary pleuropulmonary synovial sarcoma. Clin Lung Cancer. 2008, 9: 257-261. 10.3816/CLC.2008.n.040.View ArticlePubMedGoogle Scholar
- Cabarcos A, Gomez DM, Lobo Beristain JL: Pulmonary carcinosarcoma: a case study and review of the literature. Br J Dis Chest. 1985, 79: 83-94.View ArticlePubMedGoogle Scholar
- Rossi G, Cavazza A, Sturm N, Migaldi M, Facciolongo N, Longo L, Maiorana A, Brambilla E: Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases. Am J Surg Pathol. 2003, 27: 311-324. 10.1097/00000478-200303000-00004.View ArticlePubMedGoogle Scholar
- Pacinda SJ, Ledet SC, Gondo MM, Langston C, Brown RW, Carmona PA, Franklin RB, Roggli VL, Cagle PT: p53 and MDM2 immunostaining in pulmonary blastomas and bronchogenic carcinomas. Hum Pathol. 1996, 27: 542-546. 10.1016/S0046-8177(96)90159-8.View ArticlePubMedGoogle Scholar
- Koss MN, Hochholzer L, O'Leary T: Pulmonary blastomas. Cancer. 1991, 67: 2368-2381. 10.1002/1097-0142(19910501)67:9<2368::AID-CNCR2820670926>3.0.CO;2-G.View ArticlePubMedGoogle Scholar
- Takahashi K, Kohno T, Matsumoto S, Nakanishi Y, Arai Y, Fujiwara T, Tanaka N, Yokota J: Clonality and heterogeneity of pulmonary blastoma from the viewpoint of genetic alterations: a case report. Lung Cancer. 2007, 57: 103-108. 10.1016/j.lungcan.2007.01.026.View ArticlePubMedGoogle Scholar
- Bodner SM, Koss MN: Mutations in the p53 gene in pulmonary blastomas: immunohistochemical and molecular studies. Hum Pathol. 1996, 27: 1117-1123. 10.1016/S0046-8177(96)90302-0.View ArticlePubMedGoogle Scholar
- Thompson L, Chang B, Barsky SH: Monoclonal origins of malignant mixed tumors (carcinosarcomas). Evidence for a divergent histogenesis. Am J Surg Pathol. 1996, 20: 277-285. 10.1097/00000478-199603000-00003.View ArticlePubMedGoogle Scholar
- Dacic S, Finkelstein SD, Sasatomi E, Swalsky PA, Yousem SA: Molecular pathogenesis of pulmonary carcinosarcoma as determined by microdissection-based allelotyping. Am J Surg Pathol. 2002, 26: 510-516. 10.1097/00000478-200204000-00015.View ArticlePubMedGoogle Scholar
- Knuutila S, Bjorkqvist AM, Autio K, Tarkkanen M, Wolf M, Monni O, Szymanska J, Larramendy ML, Tapper J, Pere H, et al: DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol. 1998, 152: 1107-1123.PubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/424/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.